Alemtuzumab (Lemtrada™)

Last Review Date: April 8, 2016
Number: MG.MM.PH.21

Medical Guideline Disclaimer
Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member’s benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, (“EmblemHealth”) has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions
Alemtuzumab (Lemtrada) is a CD52-directed cytolytic monoclonal antibody indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS).

Dosage and Administration
Lemtrada Package Insert

Related Medical Guideline
Alemtuzumab (Campath®)
Off-Label Use of FDA-Approved Drugs and Biologicals

Guideline
Alemtuzumab (Lemtrada) is considered medically necessary for the treatment of relapsing-remitting multiple sclerosis (RRMS) when both of the following criteria are met:

1. Prior pharmacotherapy with ≥ 2 FDA-approved alternative drugs specific to MS (e.g., interferons, glatiramer) with drug-intolerance or failure to achieve adequate response
2. Human immunodeficiency virus (HIV) negative

Limitations/Exclusions
Alemtuzumab (Lemtrada) is considered investigational and not medically necessary when the medically necessary criteria are not met and including, but not limited to, the following diagnoses:

1. Primary progressive MS (PPMS)
2. Secondary progressive MS (SPMS)
Applicable Procedure Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0202</td>
<td>Injection, alemtuzumab, 1 mg</td>
</tr>
</tbody>
</table>

Applicable Diagnosis Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>G35</td>
<td>Multiple sclerosis</td>
</tr>
</tbody>
</table>

References